Bradley Radoff and Jumana Capital disclosed a 7.6% stake in Genesco (NYSE: GCO) via Schedule 13D filing, putting the footwear retailer on notice. The coalition acquired 1.14 million shares at an average cost basis near $28, establishing a position worth approximately $41 million at recent pricing. Genesco's stock rose 8.2% on the disclosure, settling at $36.15 before profit-taking trimmed gains.

Genesco operates 1,425 retail locations across North America, anchored by Journeys, Johnston & Murphy, and Schuh. The company posted $2.24 billion in trailing twelve-month revenue but carries $147 million in net debt against shrinking EBITDA margins. Same-store sales declined 3.8% in the most recent quarter as mall traffic patterns shifted and promotional intensity compressed gross margins by 180 basis points year-over-year. Management has closed 87 underperforming doors in the past eighteen months while attempting to pivot toward direct-to-consumer channels that still represent only 22% of total revenue.

Radoff's entry matters because his prior campaigns at retail-adjacent firms resulted in asset sales, board refreshes, or outright takeouts within 14-18 months. His last three disclosed positions—all sub-$1 billion market cap retailers—saw strategic reviews initiated within 90 days of 13D filing. Jumana Capital, a Dallas-based firm managing $320 million, typically co-invests in situations where operational leverage exists but capital allocation has been timid. Genesco repurchased only $18 million in stock over the past year despite trading at 5.2x forward EBITDA, well below the 7.8x peer median for specialty footwear. The company's real estate footprint—63% mall-based—creates optionality for sale-leaseback transactions that could unlock $80-120 million in proceeds at prevailing cap rates.

The coalition has not yet requested board seats or outlined specific demands, but the 13D filing language signals intent to engage on "strategic alternatives" and "operational efficiency." Genesco's CEO, Mimi Vaughn, has been in the role since 2020 and faces a board with four directors serving beyond 12 years. Activist-driven governance changes at comparable firms have preceded either accelerated store closures with margin expansion or takeout bids from private equity firms seeking to consolidate branded footwear portfolios. Genesco's licensing agreements with NFL and NCAA provide defensive moats, but the activist thesis likely centers on unlocking value through aggressive capital return or a strategic buyer willing to pay 8-9x EBITDA.

Allocators should monitor for 13D amendments within 30 days, proxy filings ahead of the June annual meeting, and any management commentary on the Q4 earnings call scheduled for mid-March. If Radoff escalates, expect activist letters or WSJ coverage within 60-90 days. The stock's 18% short interest creates technical volatility if a strategic review is announced.

Genesco has $87 million in convertible notes maturing in 2025, which will force capital structure decisions regardless of activist pressure.